Alaa Hamza Abbas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alaa Hamza Abbas has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Hayder Ridha-Salman
Al-Mustaqbal University, College of Pharmacy, Babylon, Iraq
6 shared publications - Ahmed Rahmah Abu-Raghif
Department of Pharmacology, College of Medicine, Al-Nahrain University, Baghdad, Iraq
3 shared publications - Abdulla Kadhim Raheem
Department of Pharmacology, College of Pharmacy, Al-Mustaqbal University, Hillah, Babylon, Iraq
1 shared publication - Adeeb Ahmed Al-Zubaidy
Department of Pharmacology, College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq
1 shared publication - Adeeb Ahmed Kadhim Al-Zubaidy
Department of Pharmacology, College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq
1 shared publication - Ali Jihad Hemid Al-Athari
Al-Mustaqbal University, College of Pharmacy, Babylon, Iraq
1 shared publication
Latest Publications
- Open Access
- 26 October 2025
- Published by Horizon E-Publishing Group in Plant Science Today
Anti-angiogenic activity of petroleum ether fraction of Mesembryanthemum cordifolium extract: Ex vivo study
Angiogenesis refers to the formation of new blood vessels from pre-existing ones. This process is essential for growth and tissue repair. However, it also plays a crucial role in supplying nourishment and oxygen to tumours, thereby facilitating their growth and metastasis. Among more than 1800 species in the Aizoaceae family, Mesembryanthemum cordifolium is one of the most abundant, owing to its pharmacological properties. Although the ethnobotanical use of M. cordifolium suggests therapeutic potential, the specific anti-angiogenic activity of its constituent fractions, particularly the non-polar components, has not been thoroughly investigated. The present study aimed to bridge this gap by evaluating the anti-angiogenic effect of the petroleum ether fraction of M. cordifolium. The whole plant was sequentially processed by defatting with n-hexane, followed by exhaustive extraction with 85 % methanol using a Soxhlet apparatus. The crude methanolic extract was then subjected to liquid-liquid fractionation to obtain petroleum ether, chloroform and ethyl acetate fractions. The petroleum ether fraction was phytochemically characterized using Gas Chromatography-Mass Spectrometry (GC-MS) and High-Performance Liquid Chromatography (HPLC). The anti-angiogenic potential was assessed using the ex vivo rat aortic ring assay. A dose-response relationship was determined by testing the fraction at five concentrations (6.25, 12.5, 25, 50 and 100 µg/mL) against a negative control (1 % DMSO). Compared with the negative control, the results showed that the petroleum ether extract of M. cordifolium inhibited the growth of blood vessels in a concentration-dependent manner. The study demonstrates that the petroleum ether fraction of M. cordifolium possesses potent anti-angiogenic properties ex vivo.
- 26 October 2025
- Published by Horizon E-Publishing Group in Plant Science Today
Open AccessAnti-angiogenic activity of petroleum ether fraction of Mesembryanthemum cordifolium extract: Ex vivo study
Angiogenesis refers to the formation of new blood vessels from pre-existing ones. This process is essential for growth and tissue repair. However, it also plays a crucial role in supplying nourishment and oxygen to tumours, thereby facilitating their growth and metastasis. Among more than 1800 species in the Aizoaceae family, Mesembryanthemum cordifolium is one of the most abundant, owing to its pharmacological properties. Although the ethnobotanical use of M. cordifolium suggests therapeutic potential, the specific anti-angiogenic activity of its constituent fractions, particularly the non-polar components, has not been thoroughly investigated. The present study aimed to bridge this gap by evaluating the anti-angiogenic effect of the petroleum ether fraction of M. cordifolium. The whole plant was sequentially processed by defatting with n-hexane, followed by exhaustive extraction with 85 % methanol using a Soxhlet apparatus. The crude methanolic extract was then subjected to liquid-liquid fractionation to obtain petroleum ether, chloroform and ethyl acetate fractions. The petroleum ether fraction was phytochemically characterized using Gas Chromatography-Mass Spectrometry (GC-MS) and High-Performance Liquid Chromatography (HPLC). The anti-angiogenic potential was assessed using the ex vivo rat aortic ring assay. A dose-response relationship was determined by testing the fraction at five concentrations (6.25, 12.5, 25, 50 and 100 µg/mL) against a negative control (1 % DMSO). Compared with the negative control, the results showed that the petroleum ether extract of M. cordifolium inhibited the growth of blood vessels in a concentration-dependent manner. The study demonstrates that the petroleum ether fraction of M. cordifolium possesses potent anti-angiogenic properties ex vivo.
- Open Access
- 5 September 2025
- Published by Springer Nature in Nutrire
- Vol. 50 (2) , 1-14
Anti-cataractogenic impact of Curcuma longa extract eye drops on rabbit model of sodium selenite-induced oxidative injury
- 5 September 2025
- Published by Springer Nature in Nutrire
- Vol. 50 (2) , 1-14
Open AccessAnti-cataractogenic impact of Curcuma longa extract eye drops on rabbit model of sodium selenite-induced oxidative injury
- 1 September 2025
- Published by University of Rzeszow in European Journal of Clinical and Experimental Medicine
- Vol. 23 (3) , 709-720
Phytochemical composition, antioxidant, antihyperlipidemic, and hepatoprotective effects of phenolic components of Iraqi sumac (Rhus coriaria)
Introduction and aim. Hyperlipidemia is a pathogenic disease associated with significant cardiovascular complications. Rhus coriaria, traditionally recognized as sumac, is abundant in numerous phenolic constituents that enhance its antioxidant, antibacterial, and anti-inflammatory characteristics. The aim was to investigate the phytochemical and pharmacological attributes of phenolic constituents of R. coriaria. Material and methods. 32 male albino mice were assigned at random into 4 groups (n=8). Group 1 (control), group 2 (induced), group 3 (atorvastatin) and group 4 (phenolic). All groups received a diet that was rich in fat for a duration of 28 days, except the control group, which instead consumed a standard diet. Group 2 received no treatment, while group 3 and group 4 received atorvastatin 10 mg/kg and phenolic fractions of R. coriaria 500 mg/kg, respectively, for a further 28 days. Lipid profiles, oxidative indicators, biochemical parameters, and liver histopathological examination were estimated. Results. Phenolic fractions substantially improved total cholesterol (167.5±2.4 vs. 280.4±17.6 mg/dL), triglycerides (181.1±12.5 vs. 238.6±11.05 mg/dL), low-density lipoprotein (109.0±1.6 vs. 209.2±16.8 mg/dL), and very low-density lipoprotein (36.2±2.5 vs. 47.7±2.21), while raising high-density lipoprotein levels (42.3±1.8 vs. 23.5±2.3 mg/dL) as opposed to the induced group (p<0.05). Furthermore, the phenolic constituents significantly reduced liver enzyme activities like alanine transaminase (27.4±1.8 vs. 45.2±2.8 U/L), aspartate aminotransferase (31.7±2.1 vs. 44.9±2.0 U/L), and alkaline phosphatase (28.0±2.1 vs.50.9±1.9 U/L), and decreased total blood bilirubin (0.6±0.08 vs. 1.7±0.1 mg/dL) and albumin (4.7±0.7 vs. 6.6±0.3 g/dL) when compared to the induced nontreated group (p<0.05). Phenolic treatment also alleviated tissue malondialdehyde (221.09±3.2 vs. 475.98±44.02 nmol/mL) and increased reduced glutathione (35.48±1.86 vs. 11.65±0.78 μg/mL) as compared to the group without induced non-treated group (p<0.05) and restored liver histopathological changes. Conclusion. Phenolic compounds have the potential to treat hyperlipidemia due to their anti-oxidative and anti-inflammatory properties.
- 1 September 2025
- Published by University of Rzeszow in European Journal of Clinical and Experimental Medicine
- Vol. 23 (3) , 709-720
Phytochemical composition, antioxidant, antihyperlipidemic, and hepatoprotective effects of phenolic components of Iraqi sumac (Rhus coriaria)
Introduction and aim. Hyperlipidemia is a pathogenic disease associated with significant cardiovascular complications. Rhus coriaria, traditionally recognized as sumac, is abundant in numerous phenolic constituents that enhance its antioxidant, antibacterial, and anti-inflammatory characteristics. The aim was to investigate the phytochemical and pharmacological attributes of phenolic constituents of R. coriaria. Material and methods. 32 male albino mice were assigned at random into 4 groups (n=8). Group 1 (control), group 2 (induced), group 3 (atorvastatin) and group 4 (phenolic). All groups received a diet that was rich in fat for a duration of 28 days, except the control group, which instead consumed a standard diet. Group 2 received no treatment, while group 3 and group 4 received atorvastatin 10 mg/kg and phenolic fractions of R. coriaria 500 mg/kg, respectively, for a further 28 days. Lipid profiles, oxidative indicators, biochemical parameters, and liver histopathological examination were estimated. Results. Phenolic fractions substantially improved total cholesterol (167.5±2.4 vs. 280.4±17.6 mg/dL), triglycerides (181.1±12.5 vs. 238.6±11.05 mg/dL), low-density lipoprotein (109.0±1.6 vs. 209.2±16.8 mg/dL), and very low-density lipoprotein (36.2±2.5 vs. 47.7±2.21), while raising high-density lipoprotein levels (42.3±1.8 vs. 23.5±2.3 mg/dL) as opposed to the induced group (p<0.05). Furthermore, the phenolic constituents significantly reduced liver enzyme activities like alanine transaminase (27.4±1.8 vs. 45.2±2.8 U/L), aspartate aminotransferase (31.7±2.1 vs. 44.9±2.0 U/L), and alkaline phosphatase (28.0±2.1 vs.50.9±1.9 U/L), and decreased total blood bilirubin (0.6±0.08 vs. 1.7±0.1 mg/dL) and albumin (4.7±0.7 vs. 6.6±0.3 g/dL) when compared to the induced nontreated group (p<0.05). Phenolic treatment also alleviated tissue malondialdehyde (221.09±3.2 vs. 475.98±44.02 nmol/mL) and increased reduced glutathione (35.48±1.86 vs. 11.65±0.78 μg/mL) as compared to the group without induced non-treated group (p<0.05) and restored liver histopathological changes. Conclusion. Phenolic compounds have the potential to treat hyperlipidemia due to their anti-oxidative and anti-inflammatory properties.
- Top Cited Papers
- 5 June 2025
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 56 (3) , 1-13
Quercetin mitigates sepsis-induced renal injury via inhibiting inflammatory and oxidative pathways in mice
- 5 June 2025
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 56 (3) , 1-13
Top Cited PapersQuercetin mitigates sepsis-induced renal injury via inhibiting inflammatory and oxidative pathways in mice
- Top Cited Papers
- 3 June 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (12) , 17089-17108
Suppressive effect of topical moxifloxacin on imiquimod-induced model of psoriasis in mice
Psoriasis is a chronic inflammatory skin disorder that is triggered by immune-mediated, genetic, and environmental factors. Moxifloxacin is a fluoroquinolone antibiotic with extended non-expected anti-inflammatory and immune-modulating effects. This study aims to investigate the possible influence of two different concentrations of moxifloxacin emulgel on psoriasis induced via imiquimod in mice. Dividing 48 mice into six groups (8 mice for each group), all groups gated imiquimod to induce psoriasis (except group I) for 7 days. The induction group (Group II) received imiquimod cream for 7 days. The vehicle group obtained emulgel base for 7 days. The rest of the groups got calcipotriol 0.005% ointment, moxifloxacin 3% emulgel, and moxifloxacin 5% emulgel, respectively, once daily for a further 7 days after the induction period. Topical moxifloxacin had important anti-psoriatic activity by diminishing the Psoriasis Area Severity Index (PASI) scores and improving histological alterations during imiquimod application. Moreover, moxifloxacin significantly lowered the levels of inflammatory biomarkers like TGF-β, TNF-α, IL-17, IL-1β, IL-23, and VEFG while increasing levels of anti-inflammatory biomarkers IL-10 and IL-37. Moxifloxacin also suppressed oxidative indicators such as MDA and elevated antioxidant enzyme levels, such as catalase. Moxifloxacin has substantial anti-psoriatic action against imiquimod-induced psoriasis through its anti-proliferative and anti-inflammatory effects. Furthermore, moxifloxacin has a restorative effect on the histopathological alterations of mice’s skin induced by imiquimod.
- 3 June 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (12) , 17089-17108
Top Cited PapersSuppressive effect of topical moxifloxacin on imiquimod-induced model of psoriasis in mice
Psoriasis is a chronic inflammatory skin disorder that is triggered by immune-mediated, genetic, and environmental factors. Moxifloxacin is a fluoroquinolone antibiotic with extended non-expected anti-inflammatory and immune-modulating effects. This study aims to investigate the possible influence of two different concentrations of moxifloxacin emulgel on psoriasis induced via imiquimod in mice. Dividing 48 mice into six groups (8 mice for each group), all groups gated imiquimod to induce psoriasis (except group I) for 7 days. The induction group (Group II) received imiquimod cream for 7 days. The vehicle group obtained emulgel base for 7 days. The rest of the groups got calcipotriol 0.005% ointment, moxifloxacin 3% emulgel, and moxifloxacin 5% emulgel, respectively, once daily for a further 7 days after the induction period. Topical moxifloxacin had important anti-psoriatic activity by diminishing the Psoriasis Area Severity Index (PASI) scores and improving histological alterations during imiquimod application. Moreover, moxifloxacin significantly lowered the levels of inflammatory biomarkers like TGF-β, TNF-α, IL-17, IL-1β, IL-23, and VEFG while increasing levels of anti-inflammatory biomarkers IL-10 and IL-37. Moxifloxacin also suppressed oxidative indicators such as MDA and elevated antioxidant enzyme levels, such as catalase. Moxifloxacin has substantial anti-psoriatic action against imiquimod-induced psoriasis through its anti-proliferative and anti-inflammatory effects. Furthermore, moxifloxacin has a restorative effect on the histopathological alterations of mice’s skin induced by imiquimod.
- Top Cited Papers
- 4 March 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (8) , 10769-10784
Protective effect of orientin on diabetic nephropathy in rat models of high-fat diet and streptozotocin-induced diabetes
Diabetic nephropathy (DN) represents the primary cause of chronic kidney disease (CKD) worldwide. Orientin is a natural bioactive flavonoid with profound immunomodulatory, anti-inflammatory, and antioxidative effects. This study aimed to investigate the nephroprotective effect of orientin on rat prototypes of high-fat diet (HFD) and streptozotocin (STZ)-induced DN. 75 male rats were divided into 5 groups of 15 rats each. Rats were fed a HFD for 4 weeks, injected with a single dose of STZ 30 mg/kg, and continued on HFD for 15 weeks. Orientin was administered daily at 40 mg/kg for 15 weeks. The diabetic group reported substantially greater fasting blood glucose, HbA1c, and renal function measures than normal controls, as well as notable kidney histological abnormalities such as interstitial inflammation, glomerular shrinkage, and tubular necrosis. Additionally, the diabetic group showed dramatically greater amounts of IL-1β, IL-6, TNF-α, TGF-β1, MDA, and a much lower level of GSH than the control group. However, orientin had no effect on the glycaemic parameters, but it dramatically reduced blood creatinine levels, prevented the development of histopathological irregularities, and minimized the renal concentrations of inflammatory and oxidative markers. Orientin may be a promising natural medication for improving diabetic nephropathy thanks to its robust anti-inflammatory and anti-proliferative properties.
- 4 March 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (8) , 10769-10784
Top Cited PapersProtective effect of orientin on diabetic nephropathy in rat models of high-fat diet and streptozotocin-induced diabetes
Diabetic nephropathy (DN) represents the primary cause of chronic kidney disease (CKD) worldwide. Orientin is a natural bioactive flavonoid with profound immunomodulatory, anti-inflammatory, and antioxidative effects. This study aimed to investigate the nephroprotective effect of orientin on rat prototypes of high-fat diet (HFD) and streptozotocin (STZ)-induced DN. 75 male rats were divided into 5 groups of 15 rats each. Rats were fed a HFD for 4 weeks, injected with a single dose of STZ 30 mg/kg, and continued on HFD for 15 weeks. Orientin was administered daily at 40 mg/kg for 15 weeks. The diabetic group reported substantially greater fasting blood glucose, HbA1c, and renal function measures than normal controls, as well as notable kidney histological abnormalities such as interstitial inflammation, glomerular shrinkage, and tubular necrosis. Additionally, the diabetic group showed dramatically greater amounts of IL-1β, IL-6, TNF-α, TGF-β1, MDA, and a much lower level of GSH than the control group. However, orientin had no effect on the glycaemic parameters, but it dramatically reduced blood creatinine levels, prevented the development of histopathological irregularities, and minimized the renal concentrations of inflammatory and oxidative markers. Orientin may be a promising natural medication for improving diabetic nephropathy thanks to its robust anti-inflammatory and anti-proliferative properties.
- 25 July 2023
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (1) , 599-616
The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice
Psoriasis is a lifelong immune-driven skin condition characterized by excessive epidermal overgrowth and inflammatory cell infiltration. Gemifloxacin is a fourth-generation fluoroquinolone with improved immunomodulatory and anti-inflammatory properties that are believed to possess an attractive role in psoriasis via suppressing the production of cytokines, chemokines, and eosinophil and neutrophil chemotaxis. The aim of this research is to investigate the ameliorative effects of prolonged topical gemifloxacin (GMF) alone and combined with clobetasol propionate (CLO) on an imiquimod (IMQ)-induced mouse model of psoriasis. Forty-eight Swiss albino mice were divided into six groups of eight. All groups except the negative controls got 62.5 mg of IMQ 5% topically for 8 days. Mice in the control group (controls) got Vaseline instead. Following the induction in the IMQ 5% group, mice in treatment groups CLO 0.05, GMF 1%, GMF 3%, and CLO + GMF obtained clobetasol propionate 0.05%, GMF 1% and 3%, and a combination of both, respectively, for an additional 8 days, rendering the experiment 16 days long. Our results revealed that gemifloxacin alleviated erythematous, thickened, and scaly psoriatic lesions and inhibited the tissue level of inflammatory cytokines, including interleukin (IL)-8, IL-17A, IL-23, tumor necrosis factor-α (TNF-α), and transforming growth factor-β1 (TGF-β1). The anti-inflammatory effect also occurred by hindering nuclear factor-kappa B (NF-κB) signaling and reversing histopathological problems. Gemifloxacin acts effectively in mitigating psoriasis-associated lesions and restricting NF-κB-mediated inflammation, recommending gemifloxacin as a promising adjuvant candidate for additional studies on the long-term treatment of autoimmune and autoinflammatory dermatoses like psoriasis. Graphical abstract
- 25 July 2023
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (1) , 599-616
The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice
Psoriasis is a lifelong immune-driven skin condition characterized by excessive epidermal overgrowth and inflammatory cell infiltration. Gemifloxacin is a fourth-generation fluoroquinolone with improved immunomodulatory and anti-inflammatory properties that are believed to possess an attractive role in psoriasis via suppressing the production of cytokines, chemokines, and eosinophil and neutrophil chemotaxis. The aim of this research is to investigate the ameliorative effects of prolonged topical gemifloxacin (GMF) alone and combined with clobetasol propionate (CLO) on an imiquimod (IMQ)-induced mouse model of psoriasis. Forty-eight Swiss albino mice were divided into six groups of eight. All groups except the negative controls got 62.5 mg of IMQ 5% topically for 8 days. Mice in the control group (controls) got Vaseline instead. Following the induction in the IMQ 5% group, mice in treatment groups CLO 0.05, GMF 1%, GMF 3%, and CLO + GMF obtained clobetasol propionate 0.05%, GMF 1% and 3%, and a combination of both, respectively, for an additional 8 days, rendering the experiment 16 days long. Our results revealed that gemifloxacin alleviated erythematous, thickened, and scaly psoriatic lesions and inhibited the tissue level of inflammatory cytokines, including interleukin (IL)-8, IL-17A, IL-23, tumor necrosis factor-α (TNF-α), and transforming growth factor-β1 (TGF-β1). The anti-inflammatory effect also occurred by hindering nuclear factor-kappa B (NF-κB) signaling and reversing histopathological problems. Gemifloxacin acts effectively in mitigating psoriasis-associated lesions and restricting NF-κB-mediated inflammation, recommending gemifloxacin as a promising adjuvant candidate for additional studies on the long-term treatment of autoimmune and autoinflammatory dermatoses like psoriasis. Graphical abstract